VTL's CEO and Managing Director, Dr Glenn Tong, said that this is a major milestone for VTL as we are now commencing the launch of both our patented nutraceutical products, NE1-Elite(R) for reduction of Delayed Onsent Muscle Soreness (DOMS) and NE1-Heart(R) for maintenance of heart health in the US.
About Azure Health Technology Limited:
Azure Health Technology Limited (NSX:VTL) develops and commercializes evidence-based nutraceuticals and pharmaceuticals based on two proprietary and patented delivery platforms for improving the bioavailability and efficacy of tocotrienols (a natural product which is one part of vitamin E).
Source:
Azure Health Technology Limited
Contact:
Glenn Tong
CEO and Managing Director
Ph: +61 (0) 412 193 350
Andrew Crook
Investor and Media Relations
Ph:+61 (0) 419 788 431
Catriona Glover
Company Secretary
Tel: +61 (0) 402 328 200